The short version of Preclinical research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Propranolol Bucindolol (has additional α1-blocking activity) Carteolol Carvedilol (has additional α1-blocking activity) Labetalol (has intrinsic sympathomimetic activity and additional α1-blocking activity) Nadolol Oxprenolol (has intrinsic sympathomimetic activity) Penbutolol (has intrinsic sympathomimetic activity) Pindolol (has intrinsic sympathomimetic activity) Sotalol (not considered a "typical beta blocker") Timolol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN onstitutes 0.44% of all hematological malignancies. Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy with features of cutaneous lymphoma (e.g. malignant plasmacytoid dendritic cell infiltrations into the skin to form single or multiple lesions) and/or leukemia (i.e. malignant plasmacytoid dendritic cells in blood and bone marrow). While commonly presenting with these clinical features, BPDCN, particularly in its more advanced stages, may also involve malignant plasmacytoid dendritic cell infiltrations in and thereby injury to the liver, spleen, lymph nodes, central nervous system, or other tissues. The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females equally but in adults is far more common (~75% of cases) in males. Blastic plasmacytoid dendritic cell neoplasm typically responds to chemotherapy regimens used to treat hematological malignancies.
P2S5 + 4 ROH → 2 (RO)2PS2H + H2S 2 (RO)2PS2H + ZnO → Zn[(S2P(OR)2]2 + H2O Monomeric Zn[(S2P(OR)2]2 appear not to exist. Instead, these complexes exist as dimers in solution or polymers in the solid form. The dissociation constant for the dimers at room temperature is 10−2 M
Sources: en.wikipedia.org
== Taxonomy == The first scientific description of Vanilla planifolia was published by Henry Charles Andrews in the eighth volume of his The Botanist's Repository. In his description he credits Charles Plumier with publishing a description of it in 1703 as the third species of the genus Vanilla. Andrews created the drawing in his book from a specimen that bloomed in a hothouse belonging to Charles Greville.
=== Controversies === In January 2025, Paetongtarn revealed that she had nearly been victimized by a scam using a message in a voice sounding identical to another world leader whom she did not disclose in which the caller was asking for donations. On 24 March 2025, a no-confidence motion was filed against Paetongtarn by Leader of the Opposition Natthaphong Ruengpanyawut, who accused her of failing to address multiple issues and serving her family and Thaksin Shinawatra's interests. The motion failed to pass at a vote on 26 March, with Paetongtarn winning 319 votes.
== Signs and symptoms == Children with sJIA are frequently severely unwell when diagnosed. They often have lost weight and are tired, feverish, experiencing myalgia and arthralgia, as well as occasional chest and stomach pain. These characteristics may overshadow the arthritis in the early stages of the disease. The presence of fever at presentation is practically universal in those with sJIA. The distinctive fever pattern associated with sJIA is characterized by temperatures that surge above 39 °C once or twice a day and then quickly fall to normal or below baseline. More than 80% of patients have a salmon-colored macular or maculopapular rash that appears along with their fever. Urticarial rash is less prevalent. The eruption is usually limited to the trunk, neck, and proximal extremities, but it might spread more widely. Macules typically measure less than 5 mm in diameter, while bigger macules may be present with center fading. The degree of erythema varies in the same patient, however, it is usually migratory and nonpruritic. The existence of arthritis must be validated before meeting the diagnostic criteria. Although arthralgias are often present at onset, arthritis may not be visible at first and can develop weeks, months, or even years later. Additionally, there is a wide range of joint involvement, from polyarticular patterns to oligoarticular patterns (four or fewer joints with arthritis). The wrists, knees, and ankles are the joints that are most frequently affected.
Half a Life (Bulychev), a 1973 novel by Kir Bulychev Half a Life (short story collection), a 1977 collection of translations of science fiction stories by Kir Bulychev Half a Life (film), a 1982 film by Romain Goupil Half a Life (novel), a 2001 novel by V.S. Naipaul Half a Life (memoir), a 2011 memoir by Darin Strauss "Half a Life", Medical Center season 6, episode 23 (1975) "Half a Life", Star Trek: The Next Generation season 4, episode 22 (1991)
Sources: en.wikipedia.org
=== Expansion and growth === When defined as "organizations with at least three state parties, a permanent headquarters or secretariat, as well as regular meetings and budgets", the number of IGOs in the world increased from about 60 in 1940 to about 350 in 1980, after which it has remained roughly constant.
Halliwell was awarded the Public Administration Medal (Silver) in 2010 by the President of Singapore for contributions to Singapore and awarded the President's Science and Technology Medal (2013) by the President of Singapore "for distinguished sustained and exceptional contributions to Singapore's Science and Engineering landscape". Halliwell was conferred the Outstanding Service Award at the NUS University Awards on 8 September 2023. In 2008, Halliwell was awarded the "Lifetime Achievement Award" by the Society for Free Radical Biology and Medicine in the US for overall sustained excellence in the field. He was described as a "Research Pioneer" by the journal Antioxidants & Redox Signaling in 2011. Same year, he was also awarded the Ken Bowman Research Award for outstanding achievements in the field of cardiovascular research from the Institute of Cardiovascular Sciences (Canada) and NUS University Award – Outstanding Researcher Award. He was elected a fellow of the American Association for the Advancement of Science in 2012. Halliwell was awarded a Doctor of Science honoris causa by King's College London in 2018. He was again identified as a "Highly Cited Scientist" for cross-disciplinary work by Clarivate Analytics in 2018. He was honoured as a Citation Laureate (2021) for "pioneering research in free-radical chemistry including the role of free radicals and antioxidants in human disease".
=== Atmosphere of Venus === The Venus Express orbiter collected Venus science data from April 2006 until December 2014. In 2008, Piccioni, et al. reported measurements of night-side airglow emission in the atmosphere of Venus made with the Visible and Infrared Thermal Imaging Spectrometer (VIRTIS) on Venus Express. They attributed emission bands in wavelength ranges of 1.40–1.49 micrometers and 2.6–3.14 micrometers to vibrational transitions of OH. This was the first evidence for OH in the atmosphere of any planet other than Earth.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.